The Thiopurine Safety Pharmacogenetic Panel is a pharmacogenetic test that analyses clinically relevant CPIC recommended alleles in the TPMT and NUDT15 genes to help assess a patient's risk of thiopurine-related toxicity and support individualized treatment. Reduced or absent TPMT and/or NUDT15 activity can increase exposure to active thiopurine metabolites and substantially increase the risk of leukopenia, neutropenia and severe myelosuppression, particularly with standard doses. Testing before thiopurine therapy can provide clinically relevant genetic information to support initial dose selection and therapeutic strategy. Drugs covered: Drugs covered: Mercaptopurine (6-MP) | Azathioprine (AZA) | Thioguanine (6-TG)
| Parameter | Details | |
|---|---|---|
| Genes Analysed | TPMT & NUDT15 | |
| Clinical Utility | Assessment of genetic susceptibility to thiopurine toxicity | |
| Application | Pre-treatment pharmacogenetic testing | |
| Therapeutic Relevance | Supports individualized starting-dose decisions | |
| Clinical Guidelines | CPIC-supported | |
| Methodology | Next Generation Sequencing (NGS) |
Test Code: MGM1135
TAT: 12 working days
Identifies patients with genetic variants associated with increased susceptibility to thiopurine-induced myelosuppression before treatment.
Evaluates both TPMT and NUDT15, providing a more comprehensive assessment of genetic factors influencing thiopurine tolerance.
Results can help clinicians determine whether standard, reduced or substantially reduced dosing or an alternative therapy should be considered based on the clinical context and current CPIC guidelines.
Please share your details to get
in touch with our experts.
